Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.","authors":"Roberto Contieri, Francesco Claps, Rodolfo Hurle, Nicolò Maria Buffi, Giovanni Lughezzani, Massimo Lazzeri, Achille Aveta, Savio Pandolfo, Francesco Porpiglia, Cristian Fiori, Biagio Barone, Felice Crocetto, Pasquale Ditonno, Giuseppe Lucarelli, Francesco Lasorsa, Gian Maria Busetto, Ugo Falagario, Francesco Del Giudice, Martina Maggi, Francesco Cantiello, Marco Borghesi, Carlo Terrone, Pierluigi Bove, Alessandro Antonelli, Alessandro Veccia, Andrea Mari, Stefano Luzzago, Ciprian Todea-Moga, Andrea Minervini, Gennaro Musi, Giuseppe Fallara, Francesco Alessandro Mistretta, Roberto Bianchi, Marco Tozzi, Francesco Soria, Paolo Gontero, Michele Marchioni, Letizia M I Janello, Daniela Terracciano, Giorgio I Russo, Luigi Schips, Sisto Perdonà, Octavian S Tataru, Mihai D Vartolomei, Riccardo Autorino, Michele Catellani, Chiara Sighinolfi, Emanuele Montanari, Savino M Di Stasi, Bernardo Rocco, Ottavio de Cobelli, Matteo Ferro","doi":"10.1016/j.urolonc.2024.11.015","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.015","url":null,"abstract":"<p><strong>Introduction: </strong>The nonmuscle invasive bladder cancer treated with BCG instillations in patients who smoke could potentially lead to poorer oncological results in the light of the new EAU risk groups classification for NMIBC that did not include BCG treated patients or smoking status.</p><p><strong>Patient and methods: </strong>Outcomes from 1313 patients with nonmuscle invasive bladder cancer treated with TURBT, re-TURBT and BCG instillations at 13 academic hospital centers, since 2002, has been included in this retrospective study. The study variables, including cumulative smoking exposure have been analyzed. A multivariable Cox proportional hazard model was used to assess associations between smoking variables and disease progression and repeated in the EAU high risk and very high-risk group. The statistical significance threshold was set at 0.05, and the statistical analysis was performed using Stata/SE version 17 (StataCorp, College Station, TX, USA).</p><p><strong>Results: </strong>Cox regression analysis revealed in 1313 patients diagnosed with T1G3 NMIBC that patients with a history of heavy and long-term smoking faced a more than twofold increased risk of disease progression compared to nonsmoker patients (HR 2.35; 95% CI: 1.7-3.2; P < 0.01) and a significantly poorer PFS for patients with a history of heavy long-term smoke exposure (P < 0.01). Patients with heavy long-term smoking exposure according to the EAU21 high-risk group had a PFS comparable to very high-risk patients and high-risk patients with heavy long-term smoking exposure showed a higher risk of progression when compared to the high-risk group (HR 1.4; 95% CI: 1.3-1.6; P < 0.01).</p><p><strong>Conclusions: </strong>This study adds valuable information on the relationship between smoking and the progression of NMIBC and BCG therapy. The findings emphasize the need for healthcare providers to consider a patient's smoking history when managing NMIBC and express the need for individualized smoking cessation counseling and individualized treatment approach.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOXP3/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion.","authors":"Onur Yazdan Balçık, Fatih Yılmaz","doi":"10.1016/j.urolonc.2024.11.017","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.017","url":null,"abstract":"<p><strong>Objective: </strong>Bladder carcinoma (BC) is a common type of cancer. Approximately 20% of BC patients have non-muscle invasive bladder cancer (NMIBC). Despite adequate BCG treatment, recurrence occurs in approximately 40% of the patients. There is no adequate prognostic marker for recurrence in a group of patients. Forkhead box P3 (FOXP3) is a regulatory T cell marker that sometimes exhibits anti-tumoral effects and can be used as a tumor marker. T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune checkpoint inhibitor of T cells. Tertiary lymphoid structures (TLS) increase malignancy and inflammation in non-lymphoid organs. Therefore, we aimed to evaluate the prognostic value of FOXP3, TIM-3, and TLS in patients with NMIBC.</p><p><strong>Methods: </strong>Patients with pathologically confirmed NMIBC were included in this study. Stromal and intraepithelial cells were evaluated separately using immunohistochemistry, and FOXP3, TIM-3, TLS, FOXP3/TLS, and TIM-3/TLS were calculated and noted. The cutoff value was determined using ROC analysis. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using univariate and multivariate Cox proportional hazard analyses.</p><p><strong>Results: </strong>The study included ninety-six patients. FOXP3/TLS high group had a better RFS than FOXP3/TLS low group (P = 0.001; HR, 0.079; 95% CI, 0.019-0.337). This was also significant in the multivariate analysis (P = 0.018; HR, 0.125; 95% CI, 0.022-0.705). In the group receiving BCG, FOXP3/TLS, FOXP3-TLS, TIM-3-TLS and TIM-3/TLS elevation were lower in patients with relapse than in patients without relapse and were statistically significant. Combined TIM-3 and FOXP3 elevation was found to be good prognostic regardless of whether it was found in intraepithelial, stromal or TLS.</p><p><strong>Conclusion: </strong>FOXP3/TLS elevation is a good prognostic and predictive marker in all non-muscle invasive bladder cancer cases and in the subgroup receiving BCG. Elevation of FOXP3-TLS, TIM-3-TLS, and TIM-3/TLS is associated with longer RFS in patients receiving BCG. Combined TIM-3 and FOXP3 elevation is indicative of a low recurrence rate in NMIBC.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated care among patients with kidney or urinary bladder cancer: An NCI patterns-of-care analysis.","authors":"Kirsten Y Eom, Bhupinder Mann, Michael T Halpern","doi":"10.1016/j.urolonc.2024.11.012","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.012","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer patients often have complex medical needs from diagnosis to survivorship/end-of-life care. Integrated care, including care coordination, multidisciplinary rounds, and supportive care services, is crucial for high-quality cancer care. Yet, factors influencing integrated care receipt are not well understood. This study describes patterns of integrated care among individuals diagnosed with kidney or urinary bladder cancer and examines patient- and hospital-level factors associated with these services.</p><p><strong>Methods: </strong>Analyzing 2019 National Cancer Institute Patterns-of-Care data, we assessed integrated care service receipt among stage I to IV kidney and stage 0a to IVb urinary bladder cancer patients aged ≥ 20 years using a stratified Surveillance, Epidemiology, and End Results registry sample. Integrated care services within 12 months postdiagnosis were identified by medical record abstraction. Multivariable logistic regression analyses identified patient, clinical, and hospital-level factors significantly associated with receipt of integrated care.</p><p><strong>Results: </strong>Significant variations in receiving integrated care were observed based on insurance status; uninsured patients less likely to receive these services. Racial/ethnic differences were also noted, as non-Hispanic white patients had higher likelihoods of receiving integrated care. Stage IV kidney cancer patients were 2.63 times [1.44-4.79] more likely to receive integrated care than stage I patients. Treatment characteristics and hospital-level factors appeared to have minimal impact on receiving these services.</p><p><strong>Conclusion: </strong>The lower likelihood of receiving integrated care among patients with no insurance and among certain racial/ethnic groups underscores gaps in equitable access to patient-centered cancer care. Future research should include patient perspectives to enhance understanding of unmet needs and influencing factors related to integrated care services.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A noninvasive comprehensive model based on medium sample size had good diagnostic performance in distinguishing renal fat-poor angiomyolipoma from homogeneous clear cell renal cell carcinoma.","authors":"Jinyan Wei, Yurong Ma, Jianqiang Liu, Jianhong Zhao, Junlin Zhou","doi":"10.1016/j.urolonc.2024.11.013","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.013","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the diagnostic value of a comprehensive model based on unenhanced computed tomography (CT) images for distinguishing fat-poor angiomyolipoma (fp-AML) from homogeneous clear cell renal cell carcinoma (hm-ccRCC).</p><p><strong>Methods: </strong>We retrospectively reviewed 27 patients with fp-AML and 63 with hm-ccRCC. Demographic data and conventional CT features of the lesions were recorded (including sex, age, symptoms, lesion location, shape, boundary, unenhanced CT attenuation and so on). Whole tumor regions of interest were drawn on all slices to obtain histogram parameters (including minimum, maximum, mean, percentile, standard deviation, variance, coefficient of variation, skewness, kurtosis, and entropy) by two radiologists. Chi-square test, Mann-Whitney U test, or independent samples t-test were used to compare demographic data, CT features, and histogram parameters. Multivariate logistic regression analyses were used to screen for independent predictors distinguishing fp-AML from hm-ccRCC. Receiver operating characteristic curves were constructed to evaluate the diagnostic performances of the models.</p><p><strong>Results: </strong>Age, sex, tumor boundary, unenhanced CT attenuation, maximum tumor diameter, and tumor volume significantly differed between patients with fp-AML and those with hm-ccRCC (P < 0.05). The minimum, mean, first percentile (Perc.01), Perc.05, Perc.10, Perc.25, Perc.50, Perc.75, Perc.90, Perc.95, and Perc.99 of the Fp-AML group were higher than those of the hm-ccRCC group (P < 0.05). Coefficient of variance, skewness, and kurtosis were lower than those in the hm-ccRCC group (all P < 0.05). Age, maximum tumor diameter, unenhanced CT attenuation, and Perc.25 were independent predictors for distinguishing fp-AML from hm-ccRCC (all P < 0.05). The comprehensive model, incorporating age, maximum tumor diameter, unenhanced CT attenuation, and Perc.25, showed the best diagnostic performance (AUC = 0.979).</p><p><strong>Conclusion: </strong>The comprehensive model based on unenhanced CT imaging can accurately distinguish fp-AML from hm-ccRCC and may assist clinicians in tailoring precise therapy, while also helping to improve the diagnosis and management of renal tumors, leading to the selection of effective treatment options.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset.","authors":"Jonathan T Ryan, William Jin, Joao G Porto, Dinno Mendiola, Tarek Ajami, Hui Yu, Brandon A Mahal, Sanoj Punnen","doi":"10.1016/j.urolonc.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.011","url":null,"abstract":"<p><strong>Purpose: </strong>To examine prostate cancer (PCa) screening disparities among ethnic groups in the U.S. using the All of Us database.</p><p><strong>Material and methods: </strong>White, Black, Hispanic, and Asian males ≥ 40 years old were included, excluding diagnosis's that conflict with PCa screening. We analyzed prostate-specific antigen (PSA) screening rates by age based on American Urological Association guidelines, using multivariable logistic regression (MLR) and a Cox time-to-event models that considered race, age, income, education, insurance, and home ownership as independent variables. Initial screening ages and biopsy rates were also compared.</p><p><strong>Results: </strong>Of 56,473 individuals, 18,088 had PSA measurements: 74% White, 15% Black, 9% Hispanic, and 2% Asian. Hispanic (20%) and Black (21%) minorities were less likely to undergo PSA screening compared to White men (39%, P < 0.001). However, minorities had their initial PSA earlier with their first test from 53-54 years old compared to White men at 58 years (P < 0.001). MLR revealed race, age, income, education, insurance type, and home ownership as screening predictors (P < 0.001). Screened Black men had higher odds of an elevated PSA (P < 0.001), but the likelihood of receiving a biopsy postelevated PSA did not significantly differ from White men (P = 0.821). Additionally, those screened at age ≥ 70 were more likely to be White, have at least a college education, and be homeowners (P < 0.001).</p><p><strong>Conclusions: </strong>White men, despite starting at a later age, are screened with PSAs more frequently than minorities, and often undergo screening at older ages outside the recommended guidelines. Black men did not have a higher rate of biopsy after having an elevated PSA compared to White men.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the effect of patient characteristics on the association between warm ischemia time and the risk of postoperative acute kidney injury after partial nephrectomy.","authors":"Pietro Scilipoti, Giuseppe Rosiello, Federico Belladelli, Francesco Pellegrino, Francesco Trevisani, Arianna Bettiga, Chiara Re, Giacomo Musso, Francesco Cei, Lucia Salerno, Zhe Tian, Pierre I Karakiewicz, Alexandre Mottrie, Isaline Rowe, Rayan Matloob, Alberto Briganti, Roberto Bertini, Andrea Salonia, Francesco Montorsi, Alessandro Larcher, Umberto Capitanio","doi":"10.1016/j.urolonc.2024.11.002","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.002","url":null,"abstract":"<p><strong>Background: </strong>The impact of warm ischemia time (WIT) on renal function after partial nephrectomy (PN) remains debated. This study investigates the effect of WIT on the relationship between preoperative comorbidities and postoperative renal function impairment in renal cell carcinoma (RCC) patients.</p><p><strong>Methods: </strong>Patients undergoing PN for T1 RCC at a European high-volume center (2000-2023) were analyzed. Logistic regressions assessed the association between patient comorbidities and acute kidney injury (AKI). Patients were stratified into low (LR), intermediate (IR), and high-risk (HR) groups based on a weighted comorbidity score derived from odds-ratio obtained from the logistic regression analysis. Interaction terms and a weighted local polynomial smoother function assessed the impact of WIT on AKI. Cox regressions and cumulative incidence were used to assess the chronic kidney disease (CKD) upstage ≥IIIB risk according to AKI and risk groups.</p><p><strong>Results: </strong>Of 1,048 patients, 802 underwent PN with warm ischemia. Among these, 339(42%), 208(26%), 255(32%) were classified as LR, IR and HR. IR (OR:1.82, P = 0.018) and HR (OR:3.01, P < 0.001) patients had a higher AKI risk compared to LR. The increase in WIT had little impact on the LR AKI probability compared to IR (OR:1.06, P = 0.001) and HR (OR:1.08, P < 0.001). The 10-year risk of CKD-upstage ≥IIIB was higher (36% vs. 12%, HR:2.40, P = 0.004) after AKI, and in the HR group (HR:2.42, P = 0.008) CONCLUSIONS: WIT predominantly affected the risk of AKI in HR patients for renal function impairment after surgery. Preoperative counseling is essential for comorbid patients, especially when planning complex surgeries with prolonged ischemia, to mitigate AKI and long-term renal impairment.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover 2 - Masthead","authors":"","doi":"10.1016/S1078-1439(24)00764-6","DOIUrl":"10.1016/S1078-1439(24)00764-6","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 1","pages":"Page IFC"},"PeriodicalIF":2.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover 3 - GF 397","authors":"","doi":"10.1016/S1078-1439(24)00768-3","DOIUrl":"10.1016/S1078-1439(24)00768-3","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 1","pages":"Page CO3"},"PeriodicalIF":2.4,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157).","authors":"Gaëlle Margue, Clément Klein, Bastien Parier, Laurence Albiges, Géraldine Pignot, Gwenaëlle Gravis, Pierre Bigot, Nathalie Baize, Alexandre Ingels, Charlotte Joly, François Audenet, Yann Vano, Thibaut Waeckel, Romain Levard, Philippe Barthelemy, Damien Ambrosetti, Virginie Verkarre, Mokrane Yacoub, Marine Gross-Goupil, Jean-Christophe Bernhard","doi":"10.1016/j.urolonc.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Complete responses to immunotherapy in metastatic kidney cancer have led to a renewed interest in primary-site surgery. The prolonged survival of these patients has prompted consideration for nephron-sparing surgery when technically feasible. Given the surgical difficulties reported in the literature, it is essential to assess the feasibility as well as functional and oncological results of partial nephrectomy (PN) after immunotherapy.</p><p><strong>Methods: </strong>Multicentric retrospective study based on UroCCR database, including all metastatic patients who underwent PN after a complete response to immunotherapy at metastatic sites. Morbidity, renal function, positive margin rate, and oncological outcomes were assessed.</p><p><strong>Results: </strong>Thirteen patients underwent PN after immune checkpoint inhibitor (ICI), between January 2019 and September 2023. Median age at surgery was 64 [50-68]; 84.6% received ICI as first-line treatment with a median duration of 11.7 [7.7-14.9] months. None of the patients had positive surgical margins, five patients (38.5%) were ypT0. Two patients (15.4%) presented intraoperative complications and 1 a severe postoperative complication. Median GFR at 3 months was 84.7 [66.6-95.2] mL/min/1.73 m2 with no significant difference from preoperative GFR. After surgery, immunotherapy was not reintroduced in ten patients (77%). Median follow- up was 25.6 [19.6-30.2] months, median treatment-free survival was 22.4 [15.8-34.7] months. RFS at 12 months and at last follow-up were 84.6% and 53.8%. OS rate at last follow-up was 92.3%.</p><p><strong>Conclusion: </strong>This series demonstrates the feasibility of partial nephrectomy following immune checkpoint inhibitor treatment, with acceptable morbidity rates and no major difficulties specifically attributable to the prior treatment. While the data suggest promising functional and oncological outcomes, further investigation is needed. The study underscores the importance of early re-evaluation of metastatic cases in multidisciplinary tumor boards.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of a postoperative nomogram based on the primary tumor score for overall survival of patients with renal cell carcinoma and inferior vena cava tumor thrombus.","authors":"Rongjin Zhang, Zhuo Liu, Min Zhang, Nan Li, Chang Liu, Yongyue Zhang, Yang Sun, Shudong Zhang, Shumin Wang","doi":"10.1016/j.urolonc.2024.10.031","DOIUrl":"https://doi.org/10.1016/j.urolonc.2024.10.031","url":null,"abstract":"<p><strong>Background: </strong>Radical surgery can achieve remarkable improvements in the survival of patients with renal cell carcinoma (RCC) and inferior vena cava tumor thrombus (IVCTT); however, not all patients can obtain the desired results. Therefore, identifying patients with poor survival after surgery is crucial for guiding follow-up adjuvant therapies and patient counseling.</p><p><strong>Objective: </strong>To evaluate the impact of primary tumor score based on tumor necrosis and tumor thrombus morphology on overall survival (OS), and create a postoperative prognostic model for patients with RCC and IVCTT.</p><p><strong>Methods: </strong>This retrospective study included 182 patients with RCC and IVCTT who underwent radical nephrectomy and thrombectomy (RNTE). Preoperative contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI), ultrasound imaging, and clinical records were collected. Kaplan-Meier analysis was used to evaluate the overall survival (OS). Prognostic factors for OS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. A nomogram was developed and internally calibrated using the bootstrap resampling method.</p><p><strong>Results: </strong>The mean follow-up time was 24.1 months (1-84.5 months), and 34.1% (62 of 182) of the patients died of all causes. The primary tumor score possesses a superior prognostic value for the primary tumor compared with the level of IVCTT and tumor size. Multivariate Cox regression analysis showed that primary tumor score, distant metastasis, nonclear cell subtype, sarcomatoid degeneration, preoperative anemia grade, and ASA level were independent prognostic factors. Based on these factors, a nomogram was built; the concordance index was 0.77, and the AUC for predicting 1-3 years OS were 0.80, 0.81, and 0.78, respectively.</p><p><strong>Conclusions: </strong>Primary tumor score is a independent prognostic factors for patients with RCC and IVCTT. Combined with 5 easily acquired prognostic factors, a postoperative nomogram was developed and internally validated, and can be used to select patients who may benefit from adjuvant therapy or aggressive surveillance regimens.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}